Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

2.1 Axicabtagene ciloleucel (Yescarta, Kite) is 'indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after 2 or more lines of systemic therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for axicabtagene ciloleucel.

2.3 The list price for axicabtagene ciloleucel is £280,451 per single infusion bag (approximately 68 ml, company submission).

2.4 The company has a commercial arrangement. This makes axicabtagene ciloleucel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.